The aim of the study was to assess the effect of the CYP19A1 gene polymorphism on selected markers of bone metabolism and hormonal parameters in women with hyperandrogenism, and whether the presence of polymorphisms of this gene may be a clinically useful marker in the prevention and treatment of disorders resulting from the hormonal disorders associated with hyperandrogenism. Here, CYP19A1 is linked to hyperandrogenism.